Indi Molecular

The core of the business revolves around its proprietary PCC agents, which are small, synthetic, peptide-based molecules. These agents are designed using a patented "click chemistry" process, enabling the precise and stable joining of molecular components. This method allows for the rapid creation of binders with high specificity and affinity, comparable or superior to monoclonal antibodies, but with the chemical properties and stability of small molecules. The company's business model is centered on leveraging this platform to discover and advance its own pipeline of drug candidates and to form strategic partnerships. A key milestone includes a 2019 collaboration with GE Healthcare to develop PET tracer candidates for monitoring immunotherapy patients. The company primarily serves the oncology and immunotherapy markets.

Indi Molecular's technology offers a dual-purpose platform for theranostics—the integration of diagnostics and therapeutics. The PCC agents can function as both precision in vivo PET imaging agents for diagnostics and as targeted delivery vehicles for therapeutics, including radiotherapy and chemotherapy. This dual functionality is achieved through a shared chelation chemistry platform that allows for the attachment of either a diagnostic radionuclide for PET imaging or a therapeutic payload. The company has developed therapeutic leads targeting overexpressed folate receptors in ovarian cancer and KRAS G12D-expressing pancreatic cancers. A significant advantage of the PCC platform is its speed, claiming the ability to move from an identified epitope to a nanomolar binding affinity agent in as little as four weeks. Initial funding included a $1.8 million seed round in 2013, followed by an $11.5 million Series A in 2017 and a $35 million Series B, contributing to a total of $49 million raised to date.